Stephen Greene, MD
Advanced Heart Failure and Transplant Cardiology · Durham, NCNPI 1003170861
Payments from drug & device makers
Across 307 payments — averaging $2402.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$124K
- Amgen$89K
- Merck$78K
- Lexicon Pharmaceuticals, Inc.$62K
- Novo Nordisk AS$54K
- Vifor (international) Ltd.$36K
- plus $296K from 23 others
Across 4 payments — averaging $1945.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$6K
- Sanofi-aventis U.S. LLC$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 20 | $123,794 |
| Amgen | 24 | $88,529 |
| Merck | 58 | $77,991 |
| Lexicon Pharmaceuticals, Inc. | 26 | $61,596 |
| Novo Nordisk AS | 13 | $53,869 |
| Vifor (international) Ltd. | 14 | $35,708 |
| Novo Nordisk | 24 | $34,836 |
| Roche Diagnostics International Ltd | 10 | $34,664 |
| AstraZeneca | 23 | $34,527 |
| E.r. Squibb & Sons, L.L.C. | 11 | $26,932 |
| Eli Lilly | 12 | $23,307 |
| Roche Diagnostics Corporation | 10 | $18,343 |
| Corcept Therapeutics | 9 | $13,664 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $13,500 |
| Lilly USA, LLC | 6 | $12,600 |
| Astrazeneca UK Limited | 10 | $10,746 |
| Bayer | 3 | $10,220 |
| Sanofi-aventis U.S. LLC | 2 | $9,906 |
| Mylan Inc. | 3 | $8,732 |
| Boehringer Ingelheim International GmbH | 1 | $8,525 |
| Recordati_rare_diseases_inc. | 7 | $8,491 |
| Vifor Fresenius Medical Care Renal Pharma Ltd. | 1 | $8,407 |
| Idorsia Pharmaceuticals US Inc | 2 | $7,254 |
| Scpharmaceuticals Inc. | 2 | $7,200 |
| Medtronic | 3 | $1,231 |
| Novartis | 6 | $1,192 |
| Urovant Sciences Inc | 1 | $820 |
| Chugai Pharmaceutical Co., Ltd. | 1 | $805 |
| Boston Scientific | 1 | $97 |
How this compares
$737,483 in reported general payments places this provider in the 90th percentile of 31 advanced heart failure and transplant cardiology providers in North Carolina.
See all advanced heart failure and transplant cardiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other advanced heart failure and transplant cardiology in Durham
- Merna HussienDurham$18K
- Richa AgarwalDurham$13K
- Fawaz Abdulaziz M AleneziDurham$2K
- Daniel BensimhonGreensboro$2.5M
- David IshizawarRaleigh$1.2M
- Dalton McLeanGreensboro$706K
- Emil MissovGreenville$582K
- Hassan AlhosainiWinston Salem$394K
- John RommelWilmington$394K
- Kishan ParikhRaleigh$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.